TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PT

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Tuesday, January 9, 2024, at 4:30 PM PT.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

CONTACT:
  Investor Relations
  Email: ir@tgtxinc.com
  Telephone: 1.877.575.TGTX (8489), Option 4
   
  Media Relations:
  Email: media@tgtxinc.com
  Telephone: 1.877.575.TGTX (8489), Option 6

Staff

Recent Posts

NuGen Announces Completion of InsuJet(TM) Training with Sol-Millennium(TM) Brazil

Toronto, Ontario--(Newsfile Corp. - July 1, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

5 hours ago

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information

Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDTNorthvale, New Jersey--(Newsfile Corp. -…

5 hours ago

Replicare Attracts Seasoned Leaders From Surgical Telepresence Space

SAN ANTONIO, July 1, 2024 /PRNewswire/ -- Replicare, a leading innovator in remote surgical telepresence…

5 hours ago

MED-LAB ANNOUNCES NEW NAME, LOOK & BUSINESS EXPANSION

MIAMI, July 1, 2024 /PRNewswire/ -- Med-Lab is excited to announce that it is changing…

5 hours ago

Notice of SysInformation Healthcare Services, LLC Data Security Event Which Affected Atlanta Perinatal Consultants, LLP

ATLANTA, July 1, 2024 /PRNewswire/ -- SysInformation Healthcare Services, LLC ("SysInformation"), d/b/a EqualizeRCM, is a professional…

5 hours ago

Segmed Unveils New Brand Identity and Introduces Openda, the Next Evolution for Its Insight Platform

Openda: Empowering Healthcare Innovation with Advanced Medical Imaging Data Solutions PALO ALTO, Calif., July 1,…

5 hours ago